OncoMatch/Clinical Trials/NCT05410717
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Is NCT05410717 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells for stage iv ovarian cancer.
Treatment: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells — This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Biomarker criteria
Required: CLDN6 expression
other cancers with expression of claudin6
Required: CLDN6 CAR expression ≥20% in autologous NK cells (≥20%)
Available autologous transduced NK cells with greater than or equal to 20% expression of Claudin6
Required: GPC3 CAR expression ≥20% in autologous NK cells (≥20%)
Available autologous transduced NK cells with greater than or equal to 20% expression of ... GPC3
Required: MSLN CAR expression ≥20% in autologous NK cells (≥20%)
Available autologous transduced NK cells with greater than or equal to 20% expression of ... Mesothelin
Required: AXL CAR expression ≥20% in autologous NK cells (≥20%)
Available autologous transduced NK cells with greater than or equal to 20% expression of ... AXL-CAR
Demographics
Prior therapy
Cannot have received: gene therapy
Had accepted gene therapy before
Lab requirements
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05410717 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require CLDN6?
Yes, CLDN6 expression is a required biomarker for enrollment.
Does this trial require CLDN6?
Yes, CLDN6 CAR expression ≥20% in autologous NK cells is a required biomarker for enrollment.
Does this trial require GPC3?
Yes, GPC3 CAR expression ≥20% in autologous NK cells is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages